HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BAY R3401

prodrug for BAY W1807 for inhibition of glycogenolysis; structure in first source

Also Known As:

BAY-R3401

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Dihydropyridines: 214
      - BAY R3401: 1
  - Furans: 85
    - BAY R3401: 1

Experts

1.	Cherrington, A D: 1 article (02/2001)
2.	Emshwiller, M G: 1 article (02/2001)
3.	Flattem, N: 1 article (02/2001)
4.	Igawa, K: 1 article (02/2001)
5.	Neal, D W: 1 article (02/2001)
6.	Shiota, M: 1 article (02/2001)

Related Diseases

1.	Hypoglycemia (Reactive Hypoglycemia) 02/01/2001 - "Each study consisted of an equilibration (-140 to -40 min), a control (-40 to 0 min), and a test period (0 to 180 min), during which BAY R3401 (10 mg/kg), a glycogen phosphorylase inhibitor, was administered orally, either alone to create mild hypoglycemia or with peripheral glucose infusion to maintain euglycemia or create mild hyperglycemia. "
2.	Hyperglycemia 02/01/2001 - "Each study consisted of an equilibration (-140 to -40 min), a control (-40 to 0 min), and a test period (0 to 180 min), during which BAY R3401 (10 mg/kg), a glycogen phosphorylase inhibitor, was administered orally, either alone to create mild hypoglycemia or with peripheral glucose infusion to maintain euglycemia or create mild hyperglycemia. "

Related Drugs and Biologics

1.	Glycogen Phosphorylase (Phosphorylase, Glycogen)
2.	Glucose (Dextrose)